Early Growth Response Gene 2 (Egr-2) Controls the Self-tolerance of T Cells and Prevents the Development of Lupuslike Autoimmune Disease
Overview
General Medicine
Authors
Affiliations
Maintaining tolerance of T cells to self-antigens is essential to avoid autoimmune disease. How self-reactive T cells are kept functionally inactive is, however, unknown. In this study, we show that early growth response gene 2 (Egr-2), a zinc-finger transcription factor, is expressed in CD44(high) T cells and controls their proliferation and activation. In the absence of Egr-2, CD44(high), but not CD44(low) T cells, are hyperreactive and hyperproliferative in vivo. The accumulation of activated CD4(+)CD44(high) T cells leads to the development of a late onset lupuslike autoimmune disease characterized by the accumulation of interferon (IFN)-gamma and interleukin (IL)-17-producing CD4(+) T cells, loss of tolerance to nuclear antigens, massive infiltration of T cells into multiple organs and glomerulonephritis. We found that the expression of cyclin-dependent kinase inhibitor p21cip1 was impaired in Egr-2-deficient T cells, whereas the expression of IFN-gamma and IL-17 in response to T cell receptor ligation was significantly increased, suggesting that Egr-2 activates the expression of genes involved in the negative regulation of T cell proliferation and inflammation. These results demonstrate that Egr-2 is an intrinsic regulator of effector T cells and controls the expansion of self-reactive T cells and development of autoimmune disease.
Lawler W, Castellanos T, Engel E, Alvizo C, Kasler A, Bshara-Corson S J Immunol. 2025; 214(1):153-166.
PMID: 40073267 PMC: 11844138. DOI: 10.1093/jimmun/vkae011.
Lawler W, Castellanos T, Engel E, Alvizo C, Kasler A, Bshara-Corson S bioRxiv. 2024; .
PMID: 38645150 PMC: 11030331. DOI: 10.1101/2024.04.09.588780.
Wang Z, Heid B, He J, Xie H, Reilly C, Dai R Immunohorizons. 2023; 7(12):898-907.
PMID: 38153351 PMC: 10759154. DOI: 10.4049/immunohorizons.2300111.
Gao Y, Wang Y, Chauss D, Villarino A, Link V, Nagashima H Nat Immunol. 2023; 24(8):1331-1344.
PMID: 37443284 PMC: 10500342. DOI: 10.1038/s41590-023-01553-7.
Zhou X, Gu Y, Wang H, Zhou W, Zou L, Li S Inflamm Res. 2023; 72(6):1215-1235.
PMID: 37314518 DOI: 10.1007/s00011-023-01742-y.